Dr. Muss Discusses Evaluating Cardiac Toxicity in Patients With Breast Cancer

Hyman B. Muss, MD
Published Online: Monday, May 12, 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Oncologists are now used to doing echocardiograms, which do not require any isotopes and yield rich results, or multigated acquisition (MUGA) scans, which yield results as one simple number.

Muss hypothesizes that in 5-10 years, the best way to monitor cardiac toxicity may be with an MRI of the heart and that those who are researching heart MRI are seeing incredible results.

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Oncologists are now used to doing echocardiograms, which do not require any isotopes and yield rich results, or multigated acquisition (MUGA) scans, which yield results as one simple number.

Muss hypothesizes that in 5-10 years, the best way to monitor cardiac toxicity may be with an MRI of the heart and that those who are researching heart MRI are seeing incredible results.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
13th Annual School of Breast Oncology® OnlineJan 29, 201724.25
Clinical Vignette Series: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 19, 20173.0
Publication Bottom Border
Border Publication